Reviewer’s report

Title: Customized Chemotherapy Based on EGFR Mutation Status for Elderly Patients with Advanced Non-Small-Cell Lung Cancer: a phase II trial

Version: 1 Date: 21 December 2011

Reviewer: Marina C Garassino

Reviewer’s report:

This is an interesting observation because patients with EGFR mutations and elderly seems to have less responses than others.

This may be due to the fact that in the clinical practice we reduce conventional doses.

It should be interesting to point out the reduction doses of both treatment for each patient and in particular for what kind of toxicity.

Finally numbers are unable to draw any conclusions.

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Needs some language corrections before being published

Statistical review: No, the manuscript does not need to be seen by a statistician.